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The rs361525 polymorphism does not
increase production of tumor necrosis
factor alpha by monocytes from alpha-1
antitrypsin deficient subjects with chronic
obstructive pulmonary disease - a pilot
study
Jennie M. Gane1,3*, Robert A. Stockley2 and Elizabeth Sapey1
Abstract
Background: Polymorphisms in the TNF-A gene have been associated with chronic obstructive pulmonary disease
(COPD) in some case-control studies. Previous work has shown that COPD/chronic bronchitis subjects with alpha-1
antitrypsin deficiency with the rs361525 TNF-α single nucleotide polymorphism have 100 times more TNF-in
spontaneous sputum than disease matched controls. Our objective was to determine if the presence of this
polymorphism increased TNF-α production by blood monocytes from COPD subjects.
Findings: Monocytes from 18 COPD/alpha-1 antitrypsin deficient subjects, with and without the rs361525
polymorphism, were cultured in the presence or absence of lipopolysaccharide. Cell-free supernatants were
analyzed by ELISA and real-time PCR performed using cDNA from extracted RNA. Baseline expression of TNF-α
messenger RNA was no different between the groups. No difference in messenger RNA or secreted protein
was observed over time in un-stimulated cells. TNF-α messenger RNA expression and protein was not higher
in lipopolysaccharide-stimulated monocytes from subjects with the polymorphism compared to cells from
patients with the wild-type allele.
Conclusions: This small pilot study did not provide an explanation for the findings of earlier observations of
the association of the rs361525 polymorphism with TNF-α in airways secretions. Possible reasons for the lack
of concordance include the study of blood rather than tissue cells, the use of a single stimulant rather than
biological secretions and the need for far greater subject numbers to overcome intra-subject variation in
monocyte TNF-α production.
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Chronic obstructive pulmonary disease (COPD) is a
debilitating disease most commonly caused by smoking.
However, only 25 % of smokers develop COPD,
suggesting other contributing factors, such as genetic
susceptibility [1]. The only well described example of
genotype influencing the development of COPD is
Alpha-1 Antitrypsin Deficiency (AATD), characterised
by deletions/substitutions within the serpinA1 gene.
The resultant reduction of neutrophil elastase-buffering
alpha-1 antitrypsin leads to the development of airflow
obstruction and emphysema [2].
There is a pressing need to identify new therapeutic
targets in COPD, to modify disease and improve out-
comes. COPD is heterogeneous and it is possible that
there are many potential targets, each affecting a subset
of patients. One such target may be tumor necrosis
factor-alpha (TNF-α) which has been implicated in the
pathogenesis of COPD in animal studies [3, 4] and
observational human studies [5]. Whilst TNF-α is not
ubiquitously raised in COPD [6] and anti-TNF-α treat-
ments are not efficacious in a generalised COPD popula-
tion [7], single nucleotide polymorphisms (SNPs) in the
TNF-A gene have been identified that might enhance
susceptibility to COPD by increasing inflammatory
output. Wood et al characterised a cohort of 424 unre-
lated patients with COPD and AATD and determined
that the rs361525 polymorphism, a G to A substitution
at position -238 in the promoter region of the gene, was
observed with greater frequency in subjects with a
chronic bronchitis phenotype [8]. Analysis of spontaneous
sputum samples from 10 subjects revealed 100 times
greater soluble TNF-α concentration compared to matched
controls, suggesting the polymorphism may affect gene
transcription. In addition, in lung secretions there was a
higher concentration of downstream pro-inflammatory
mediators, greater decline in lung function and lower BMI,
indicating a more aggressive disease phenotype. No differ-
ence in serum concentration of TNF-α was observed and
was low in both groups which may reflect rapid binding to
tissue receptors preventing its detection [9].
Alpha-1 antitrypsin is involved in the modulation of
TNF-α biosynthesis and AATD patients are known to
have increased activation of the TNF-α pathway [10].
Therefore patients with both AATD and a pro-
inflammatory TNF-α SNP might be more exposed to
TNF-α inflammation, enhancing the cellular and
clinical effects of the polymorphism.
We hypothesised that monocytes (a principal TNF-α
producing cell) from subjects with AATD and COPD
would produce more TNF-α if they carried the rs361525
polymorphism and that this would have an enhancing
downstream effect on other monocyte functions relevant
to COPD, such as phagocytosis and cytokine production.
As no previous experiments had been conducted in
monocytes with the rs361525 polymorphism from this
patient group, it was not possible to power the current
studies and hence the work presented here should be
considered as a pilot study.
Methods
This study was conducted following ethical approval
from the National Research Ethics Service Committee
West Midlands, UK (reference number LREC-3359/
3359-A). Patients with AATD and COPD were recruited
from the UK AATD registry, held in Birmingham, UK,
following the provision of written informed consent. All
patients were clinically stable and exacerbation free for
at least six weeks prior to recruitment. Patients were
selected following careful matching for clinical criteria
(described in Table 1). Subjects with the polymorphism
are referred to as AG and those with the wildtype allele,
GG. Monocytes were extracted using the Dynabeads®
Untouched™ Human Monocytes kit (Life Technologies,
Paisley, UK). Cells were re-suspended in culture medium
(sterile Roswell Park Memorial Institute medium 1640
(Sigma Chemicals Ltd, Poole, UK) supplemented with
10 % fetal calf serum, 10%L-glutamine and 10 % penicil-
linV and streptomycin and cultured at 37 °C and in 5 %
CO2. Monocytes were plated at a concentration of 0.25
(for mRNA experiments) or 0.45 million per ml (in
duplicate for ELISA experiments) of culture medium.
Salmonella Enteritidis derived lipopolysaccharide (LPS)
(100 ng/ml; Sigma Chemicals Limited, Poole, UK) was
chosen as the TNF-α stimulant after conducting
concentration-response and time-course experiments in
healthy control monocytes to confirm it elicited the
greater response, compared to a number of other stim-
uli, with a peak time point for TNF-α protein (6 h post
LPS). An enzyme-linked immunosorbant assay (ELISA)
was used to measure TNF-α in the cell-free supernatant
according to manufacturer instructions (R&D Systems,
Abingdon, UK). The plates were read using a Synergy
HT microplate reader (Biotech, GMI, Ramsey, USA). All
samples and standards were run in duplicate. mRNA
was extracted from each cell pellet using the Isolate
RNA Minikit (Bioline, London, UK). Median 260/280
ratio of RNA samples was 2.1 (IQR 1.8-2.6). RNA
samples were reverse transcribed using a High Capacity
RNA-to-cDNA Kit (Life Technologies, Paisley, UK) in a
Takara Thermal Cycler PCR machine (Takara Bioeurope,
Saint-Germain-en-Laye, France). Real-time quantitative
polymerase chain reaction (PCR) was carried out to
quantify the expression of each gene of interest. Com-
plementary deoxyribonucleic acid (cDNA) was mixed
with Light Cycler 480 Probe PCR Master master mix
(Roche Applied Science, Burgess Hill, UK), PCR-grade
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water and the relevant fluorescein isothiocyanate-labelled
TaqMan gene expression assay (Life Technologies, Paisley,
UK), in each well of the plate. The reaction was run on a
Roche Lightcycler 480 (Roche Applied Science, Burgess
Hill, UK), for 45 amplification cycles. The Assay-on-
Demand numbers for the TaqMan assays were:
glyceraldehyde 3-phosphate dehydrogenase (GAPDH):
Hs99999905_m1; TNF-α: Hs00174128_m1. Where an
individual normalising gene can be shown to be stably
expressed in the model under study it is deemed
acceptable to use only that one [11]. Stable reference
genes have been classified as those in which the average
fold change from the mean expression was less than 2 and
the maximum variability in fold change less than 5 [12].
GAPDH was found to be stably expressed in a random
selection of 64 samples (from different subjects and under
a variety of experimental conditions) with a mean fold
change from the mean CT value of 1.7 and a maximum
fold change of 4.6. Singleplex reactions with equal starting
quantities of cDNA were conducted. Samples were run in
duplicate and the average of two cycle threshold values
taken. The 2-ΔCT formula was used to calculate the relative
expression of mRNA [13]. Data is presented as median
and IQR and differences between groups tested with a
Mann Whitney U test. Data was analysed using the SPSS
statistical program (version 20.0 Chicago, USA).
Results
Table 1 shows the characteristics of study subjects.
There were 9 subjects in each group. Data for mRNA
work was available for only 8 subjects in each group
(due to a technical issue in mRNA extraction for one
subject). Patients were matched closely, as shown in
Table 1. There were no statistically significant differences
between the groups.
Expression of TNF-α mRNA in freshly isolated un-
stimulated monocytes was low and there was no
difference between AG and GG subjects (Fig. 1). No
difference in mRNA expression or secreted protein was
observed between the two groups in monocytes cultured
without any stimulus (Fig. 2a and b). LPS-stimulated
monocytes isolated from AG patients did not show more
mRNA expression or protein concentration compared to
the GG (wild type) (Fig. 2c and d). We hypothesized that
measuring TNF-α on one occasion may be insufficient
to determine a true difference between groups, should
intra-subject variation in TNF-α secretion over time be
high. Monocytes from 3 healthy subjects were therefore
isolated twice weekly (3-4 days apart) for 3 weeks,
stimulated with 100 ng/ml of LPS, and TNF-α concen-
tration in the cell-free supernatant measured at 3 h.
Figure 3 shows the values over 3 weeks for each subject.
Coefficient of variation percentage values for subjects
Table 1 Characteristics of study subjects
Characteristic rs361525 + ve (AG/AA) rs361525 -ve (GG) P value (2- tailed)
N 9 9
(8 AG/1 AA)
Presence of COPD 9/9 9/9
Age in years 51 (50–65) 60 (49–61) 0.8
Male 7 (77.8) 7 (77.8)
AATD level (micromolar) 3.8 (0.4) 4.0 (0.5) 0.8
BMI 21.2 (21.0–23.8) 23.2 (22.0–26.0) 0.3
Smoking hx Current 1 0
Ex/never 7/1 8/1
Pack years 22 (10–28) 22 (9–30) 0.9
FEV1 (L) 1.4 (0.1) 1.4 (0.2) 0.8
FEV1 % predicted 37.7 (33.4–43.4) 33.6 (32.6–54.6) 0.9
FEV1/FVC ratio (%) 32.0 (28.0–34.0) 32.2 (23.0–33.0) 0.5
KCO % predicted 53.9 (4.6) 52.0 (4.8) 0.8
Emphysema on HRCT 8/9 9/9
Chronic bronchitis phenotype 4/9 5/9
Bronchiectasis on HRCT 4/9 5/9
Inhaled steroids 8/9 9/9
Median exacerbations per year 1.0 (1.0–2.0) 0.5 (0–1.0) 0.3
The table shows key characteristics of subjects with (AG/AA) and without (GG) the rs361525 TNF-α polymorphism. Subjects were matched as closely as possible.
Data is given as mean (SE) where normally distributed and median (IQR) where not normally distributed. An independent t-test was used to detect any difference
between groups for the former data and a Mann Whitney U test for the latter
Gane et al. Journal of Negative Results in BioMedicine  (2015) 14:20 Page 3 of 6
Fig. 1 Baseline expression of TNF-α mRNA in freshly isolated monocytes from patients with and without the rs361525 TNF-α polymorphism. Columns
show median (IQR) ΔCT values for TNF-α mRNA expression (normalised to GAPDH). Differences between subject groups were assessed with a Mann
Whitney U test. There was no significant increase in TNF-α mRNA expression in the AG monocytes
Fig. 2 TNF-α production over time by monocytes from patients with and without the rs361525 TNF-α polymorphism. a ΔCT values for TNF-α mRNA
expression (normalised to GAPDH) in un-stimulated monocytes cultured over 24 hours. b Concentration of sTNF-α in the supernatant of un-stimulated
monocytes cultured for 6 and 24 hours. c ΔCT values for TNF-α mRNA expression in LPS-stimulated monocytes cultured over 24 hours.
d Concentration of sTNF-α in the supernatant of LPS-stimulated monocytes cultured for 6 and 24 hours. Results are displayed as median
(with IQR). There was no significant increase in TNF-α mRNA expression or protein concentration in the AG monocyte group
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one to three were 26.9, 48.4 and 17.7 %. These data
were used to calculate that a sample size of 40 patients
per AG/GG group would be required to demonstrate a
true 20 % difference in sTNF-α concentration in the
supernatants six hours post LPS stimulation with
approximately 80 % power.
Discussion
The pilot studies presented here did not support the
findings in the sputum of COPD/AATD patients with
the rs361525 polymorphism, which was surprising
given the magnitude of difference observed in the
airways [9]. It is clear from subsequent experiments
studying the intra-subject variation in TNF-α that
large numbers of subjects in each group would be
required to have adequate power to detect even a
modest difference in production should this exist in
monocytes in relation to this stimulus and hence
further studies were not conducted.
There are other possible explanations for the lack of
expected effect. Although LPS has been shown to induce
transcription of TNF-α mRNA in immortalised cells of
the monocyte lineage with the AG genotype using a
reporter gene assay [14], the same study demonstrated
that multiple hits are required to maximally potentiate
the effects of the polymorphism. Specifically, binding of
thyroid hormone receptor to the A allele in addition to
LPS-induced nuclear factor kappa beta was necessary. It
is possible that the complex cytokine milieu in the lungs
of COPD patients is such that multiple mechanisms are
in place to enhance TNF-α mRNA transcription in
subjects with the A allele. By the same rationale it may
be that the effects of the polymorphism are specific to
the airways of COPD/AATD patients with chronic
bronchitis, due to specific local stimulating factors, again
potentially reducing the power if this is the critical
disease phenotype. In the current study only 50 % of
subjects had chronic bronchitis in addition to emphy-
sema, and these low numbers prevented further analysis
of any clinical subgroup. Finally, monocytes may not be
the relevant cell to study. The increased TNF-α concen-
tration in the sputum might reflect output specifically
from macrophages, T-cells or bronchial epithelial cells.
Indeed, the original study found no difference in
systemic levels of TNFα between groups perhaps
suggesting this is a compartment specific finding [9].
In summary our findings did not support our
primary hypothesis but are consistent with the litera-
ture describing the effects of this particular poly-
morphism. Studies report positive, negative and no
effects, in a range of cells types, employing a wide
variety of techniques to measure output and in differ-
ent disease states [9, 14–25]. This study reflects the
inherent difficulty in studying the effects of SNPs at a
cellular level and we suggest further investigation of
the rs361525 SNP should focus on airway derived cells
and local transcription factors.
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Fig. 3 TNF-α secretion by LPS-stimulated monocytes over three weeks. Monocytes from 3 healthy subjects (2 female) were isolated twice weekly
for 3 weeks and stimulated in duplicate with 100 ng/ml of LPS for 3 hours. TNF-α concentration in the cell-free supernatant was measured using
ELISA. Coefficient of variation (CV%) values for each subject are shown
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